• Reduce the risk of SSI.

    Reducing Readmissions in Minnesota

    Reduce the risk of SSI.

    • Reducing Hospital-Acquired Complications

      3M™ Skin and Nasal Antiseptic helps address the concerns about surgical site infections (SSI) caused by Staphylococcus aureus (S. aureus), including methicillin-resistant Staphylococcus aureus (MRSA). A growing body of evidence demonstrates that utilizing this intervention as part of a preoperative protocol helps to reduce the risk of SSI. 2 3 4 5 6 7 8 9

      Eight distinct, clinical studies have confirmed 3M™ Skin and Nasal Antiseptic’s efficacy – both individually, and as part of a preoperative bundle.

      • Infection rate was reduced by 71% when nasal antiseptic was included in a perioperative decontamination protocol.3
      • Nasal Antiseptic was associated with $62,302 in readmission cost avoidance. 8
      • 100% reduction in SSI in Orthopedic Total Hip and Knee Arthoplasty patients following implementation of a ‘best practices’ operative checklist, which included use of 3M Skin and Nasal Antiseptic.7 The overall rate of SSI decreased significantly following intranasal antisepsis p=0.03. 6

      S. aureus is the leading cause of SSI10 with approximately 80 percent of S. aureus infections caused by the patient’s own nasal flora.11 This product is designed to work within the preoperative process to quickly and effectively reduce S. aureus colonization in the nares2, healthcare providers can be confident their patients are entering surgery with a reduced risk of infection.


      1 3M Study 05-01132

      2 Phillips M, Rosenberg A, Shopsin B, et al. Preventing Surgical Site Infections: A randomized, open-label trial of nasal mupirocin ointment and nasal povidone-iodine solution. Infect Control Hosp Epidemiol. 2014; 35(7): 826-832.

      3 Bebko SP, Green DM, Awad SS. Effect of a Preoperative Decontamination Protocol on Surgical Site Infections in Patients Undergoing Elective Orthopedic Surgery With Hardware Implantation. JAMA Surg. Published online March 04, 2015. doi:10.1001/jamasurg.2014.3480.

      4 Torres EG, Lindmair-Snell JM, Langan JW, Burnikel BG. Is preoperative nasal povidone-iodine as efficient and cost-effective as standard methicillin-resistant Staphylococcus aureus screening protocol in total joint arthroplasty? J Arthroplasty. 2016; 31: 215-218.

      5 Flynn N, Carr M. Skin and Nasal Antiseptic Use in the Prevention of Post-Operative Infections. Presented at the SHEA Conference, Orlando, FL, May 2015.

      6 Brown L, Shelly M, Greene L, et al. The Effect of Universal Intranasal Povidone Iodine Antisepsis on Total Joint Replacement Surgical Site Infections. Presented at the APIC National Conference, Anaheim, CA, June 2014.

      7 Hogenmiller J, Hamilton J, Clayman T, et al. Preventing Orthopedic Total Joint Replacement SSIs through a Comprehensive Best Practice Bundle/Checklist. Presented at the APIC National Conference, Baltimore, MD, June 2011.

      8 Waibel ML. Revisiting Process Improvement for Total Joint Arthroplasty SSI. Presented at the APIC National Conference, Fort Lauderdale, FL, June 2013.

      9 Osborn N, Reynolds L. Embedding an Infection Preventionist (IP) in the OR. Presented at the AORN Surgical Conference and Expo, Denver, CO, March 2015.

      10 Sievert DM, Ricks P, Edwards JR, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: Summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009–2010. Infect Control Hosp Epidemiol. 2013; 34(1):1-14.

      11 Perl TM, Cullen JJ, Wenzel RP, et al. Intranasal mupirocin to prevent postoperative Staphylococcus aureus infections. N Engl J Med. 2002; 346(24): 1871-1877.